Literature DB >> 1082814

Impaired responsiveness to folinic acid protection in methotrexate-resistant L5178Y cells.

J H Goldie, S I Harrison, L A Price, B T Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1082814     DOI： 10.1016/0014-2964(75)90097-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  2 in total

1.  Phase I clinical trial and pharmacology of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF).

Authors:  R de Jager; D Dupont; J J Rodzynek; C Dorlet; G Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

2.  Phase II clinical trial of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine) and folinic acid (CF) in solid tumors.

Authors:  R de Jager; A Brugarolas; M Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.